An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by Scottsdale Healthcare.
Recruitment status was  Active, not recruiting
National Foundation for Cancer Research
Translational Genomics Research Institute, Phoenix, Arizona.
Information provided by (Responsible Party):
Glen Weiss, Scottsdale Healthcare Identifier:
First received: September 27, 2011
Last updated: September 28, 2011
Last verified: September 2011

When a patient with advanced cancer consults with a member of the Phase I drug development team, the investigators utilize all information possible to try to select a therapy for that patient which has the best chance of working for them. This information includes:

  1. Past published information
  2. Clinical experience and judgement
  3. Immunohistochemistry for specific targets (e.g., ER)
  4. Standard sequencing (e.g., for K-Ras) and other methods now available.

The investigators have a new tool which warrants early exploration for what role it might eventually play in the process of selecting the best therapy for an individual patient. The basis of the current ancillary exploratory study is to gain initial experience with the operational aspects of this whole genome sequencing in this setting.

Advanced Cancer

Study Type: Observational
Official Title: An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advanced Refractory Cancer

Resource links provided by NLM:

Further study details as provided by Scottsdale Healthcare:

Biospecimen Retention:   Samples With DNA

Biopsy of an accessible lesion

Estimated Enrollment: 10
Study Start Date: September 2011
Estimated Study Completion Date: March 2014
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Detailed Description:
  1. To measure the time from biopsy to completion and final analysis of Whole Genome Sequencing (WGS) on patient tumor and non-tumor samples.
  2. To examine the frequency with which useable sequence data is obtained as a function of tumor volume received and percent tumor involvement in the biopsy
  3. To identify the frequency with which potential targets and pathways for therapy are discovered.
  4. To observe for any evidence that if anti-tumor activity from treatment is noted how would the genome sequencing have correlated with that activity.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with advanced refractory cancer


Inclusion Criteria:

  • Have a life expectancy of greater than 3 months.
  • Patients must have a diagnosis of histologically or cytologically confirmed advanced incurable cancer which has progressed on one or more prior chemotherapeutic, hormonal or biological regimens for advanced disease.
  • Be a good medical candidate for and willing to undergo a biopsy or surgical procedure to obtain tissue, which may or may not be part of the patient's routine care for their malignancy.

Exclusion Criteria:

  • Patients with symptomatic CNS metastasis.
  • Known HIV, HBV or HCV infection requiring antiviral therapy.
  • Pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception.
  • Inaccessible tumor for biopsy
  Contacts and Locations
Please refer to this study by its identifier: NCT01443390

United States, Arizona
Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare
Scottsdale, Arizona, United States, 85258
Sponsors and Collaborators
Scottsdale Healthcare
National Foundation for Cancer Research
Translational Genomics Research Institute, Phoenix, Arizona.
Principal Investigator: Glen J Weiss, M.D. Scottsdale Healthcare
  More Information

No publications provided

Responsible Party: Glen Weiss, Director, Thoracic Oncology Program, Scottsdale Healthcare Identifier: NCT01443390     History of Changes
Other Study ID Numbers: SCRI-CA_004
Study First Received: September 27, 2011
Last Updated: September 28, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Scottsdale Healthcare:
Whole genome sequencing
Advanced Refractory Cancer

Additional relevant MeSH terms:
Neoplasms processed this record on April 14, 2014